Cyril B Dousson

Cyril B Dousson
Ai-biopharma · Medicinal Chemistry & Chemoinformatics

PhD
Ai-biopharma

About

83
Publications
3,981
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
657
Citations
Introduction
Research and development of new Antiviral candidate drugs (HBV & Coronavirus), Drug Discovery, Medicinal Chemistry, Artificial Intelligence & Chemoinformatic.
Skills and Expertise
Computer Aided Drug Design
Drug Design
Drug Discovery
Medicinal Chemistry
Medicinal and Pharmaceutical Chemistry
Synthetic Organic Chemistry
Small Molecule Drug Discovery
Medical Chemistry
Anti-Cancer Drug Design and Discovery
Pharmaceutical Chemistry
Additional affiliations
February 2018 - present
Ai-biopharma
  • Medicinal Chemistry & Chemoinformatics
  • Montpellier, France
Position
  • CEO
Description
  • www.ai-biopharma.com
August 2014 - January 2018
Merck & Co.
Merck & Co.
  • Research Laboratories
  • Montpellier, France
Position
  • Head of Department
August 2003 - August 2014
Idenix Pharmaceuticals, Inc.
Idenix Pharmaceuticals, Inc.
  • Medicinal Chemistry
  • Montpellier, France
Position
  • Head of Department
Education
September 1997 - November 2000
University of Liverpool
University of Liverpool
Field of study
  • Chemistry

Network

Cited
View All
Cited By
View All

Projects

Projects (13)
Antiviral - pan-Coronavirus Polymerase Inhibitors (2nd generation)
Project
Research and development of second generation Coronavirus polymerase inhibitors with wider coverge and better efficacy and tolerability.
Antiviral - HBV Polymerase Inhibitors (3rd generation)
Project
Develop AIB-001, a new oral liver targeted HBV Polymerase inhibitor as the Backbone component of a combination therapy for HBV Functional Cure.
Antiviral - HIV Nuc Reverse Transcriptase Inhibitors
Project
Antiviral - HIV Nucleos(t)ide Reverse Transcriptase Inhibitors